Literature DB >> 12634982

Short-acting parenteral antipsychotics drive choice for classical versus atypical agents.

Gerard W K Hugenholtz1, Joost J Stolker, Eibert R Heerdink, Willem A Nolen, Hubert G M Leufkens.   

Abstract

OBJECTIVE: The objective of this study was to investigate which antipsychotics (classical versus atypical) are prescribed in a psychiatric hospital and which determinants affect the choice for one of these two classes of antipsychotics in newly admitted patients.
METHODS: In a retrospective cohort design, 522 newly admitted patients were followed from the date of admission until discharge from the hospital. In the cohort of newly admitted patients treated with an oral antipsychotic, a nested case-control study was conducted considering recipients of an atypical agent as cases. Controls were all other cohort members. The association of patient characteristics and the choice between classical versus atypical antipsychotics was studied using logistic regression analysis. The same analysis was performed with adjustment for possible confounding factors (age group, gender, DSM-IV diagnoses, use of short-acting parenteral antipsychotic, global assessment of functioning score, involuntary admissions and involuntary measures).
RESULTS: Patients treated with classical oral antipsychotics were more often previously treated with short-acting parenteral antipsychotics than patients treated with atypical antipsychotics (40.8% vs 15.2%; adjusted OR=0.20 95% CI=0.09-0.44). No statistically significant difference was found between patients with different severities of disease. DISCUSSION: Availability of injectable forms seems to drive the choice for oral antipsychotic agents. Future introductions of short-acting parenteral atypical antipsychotics may have a large impact on first-choice oral antipsychotic treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12634982     DOI: 10.1007/s00228-002-0545-3

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  The efficacy of psychotropic drugs: implications for power analysis.

Authors:  J M Davis; P G Janicak; Z Wang; R D Gibbons; R P Sharma
Journal:  Psychopharmacol Bull       Date:  1992

2.  Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association.

Authors: 
Journal:  Am J Psychiatry       Date:  1997-04       Impact factor: 18.112

Review 3.  Novel antipsychotics and negative symptoms.

Authors:  H J Möller
Journal:  Int Clin Psychopharmacol       Date:  1998-03       Impact factor: 1.659

Review 4.  Haloperidol versus placebo for schizophrenia.

Authors:  C B Joy; C E Adams; S M Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2001

Review 5.  Zuclopenthixol acetate in the treatment of acute schizophrenia and similar serious mental illnesses.

Authors:  M Fenton; E S Coutinho; C Campbell
Journal:  Cochrane Database Syst Rev       Date:  2001

6.  [New antipsychotics in the treatment of schizophrenia. A European survey].

Authors:  Y Sarfati; V Olivier; M Bouhassira
Journal:  Encephale       Date:  1999 Nov-Dec       Impact factor: 1.291

7.  How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia.

Authors:  R Rosenheck; D Evans; L Herz; J Cramer; W Xu; J Thomas; W Henderson; D Charney
Journal:  Schizophr Bull       Date:  1999       Impact factor: 9.306

8.  Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study.

Authors:  K Wahlbeck; M Cheine; K Tuisku; A Ahokas; G Joffe; R Rimón
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2000-08       Impact factor: 5.067

9.  A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.

Authors:  Jonathan M Meyer
Journal:  J Clin Psychiatry       Date:  2002-05       Impact factor: 4.384

10.  Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts.

Authors:  R M Herings; A Bakker; B H Stricker; G Nap
Journal:  J Epidemiol Community Health       Date:  1992-04       Impact factor: 3.710

View more
  3 in total

1.  A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation.

Authors:  Theodore D Satterthwaite; Daniel H Wolf; Robert A Rosenheck; Raquel E Gur; Stanley N Caroff
Journal:  J Clin Psychiatry       Date:  2008-12-02       Impact factor: 4.384

2.  Predicting rehospitalization in patients treated with antipsychotics: a prospective observational study.

Authors:  Heshu Abdullah-Koolmees; Helga Gardarsdottir; Lotte A Minnema; Kamjar Elmi; Lennart J Stoker; Judith Vuyk; Laurette E Goedhard; Toine C G Egberts; Eibert R Heerdink
Journal:  Ther Adv Psychopharmacol       Date:  2018-03-16

3.  The effect of non-adherence to antipsychotic treatment on rehospitalization in patients with psychotic disorders.

Authors:  H Abdullah-Koolmees; S Nawzad; T C G Egberts; J Vuyk; H Gardarsdottir; E R Heerdink
Journal:  Ther Adv Psychopharmacol       Date:  2021-06-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.